Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease. As more potent FLT3...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Galanis, Allison, Ma, Hayley, Rajkhowa, Trivikram, Ramachandran, Abhijit, Small, Donald, Cortes, Jorge, Levis, Mark
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2014
Предметы:
Myeloid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3879910/
https://ncbi.nlm.nih.gov/pubmed/24227820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-529313
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы